Does macrobid (nitrofurantoin) provide adequate coverage for Streptococcus anginosus in a urinary tract infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nitrofurantoin Coverage for Streptococcus anginosus in Urinary Tract Infections

Nitrofurantoin provides adequate coverage for Streptococcus anginosus in uncomplicated lower urinary tract infections, as it demonstrates broad-spectrum activity against Gram-positive cocci including streptococcal species and achieves high urinary concentrations. 1

Microbiologic Activity Against Streptococcal Species

  • Nitrofurantoin exhibits strong in-vitro activity against streptococcal species, including Group B Streptococcus (Streptococcus agalactiae), and is considered an appropriate oral option for uncomplicated lower urinary tract infections caused by Gram-positive cocci 1

  • The drug demonstrates broad-spectrum bactericidal activity against both Gram-positive and Gram-negative pathogens, including Enterococcus species (which are also streptococci), with 88% susceptibility rates documented in clinical studies 2, 3

  • International guidelines endorse nitrofurantoin 100 mg orally every 6 hours as first-line therapy for uncomplicated UTIs caused by resistant Gram-positive cocci, reflecting confidence in its activity against streptococcal pathogens 1

Guideline-Based Recommendations for Empiric UTI Treatment

  • For uncomplicated cystitis, nitrofurantoin 100 mg twice daily for 5 days is the preferred first-line agent, achieving adequate urinary concentrations with minimal resistance and low collateral damage to normal flora 4, 1

  • Current guidelines from the Infectious Diseases Society of America, American Urological Association, and European Association of Urology all position nitrofurantoin as a first-line empiric treatment option for uncomplicated lower UTIs 4, 1

  • The drug has been successfully used for over 60 years and retains excellent activity against common uropathogens despite prolonged use, with resistance rates remaining low 5, 6

Critical Limitations and Contraindications

  • Nitrofurantoin should NOT be used for pyelonephritis or upper urinary tract infections because it achieves high urinary concentrations but poor tissue penetration; patients with fever, flank pain, or systemic symptoms require parenteral agents such as ampicillin, ceftriaxone, or fluoroquinolones instead 1

  • The drug is contraindicated in patients with any degree of renal impairment (creatinine clearance <60 mL/min), in the last trimester of pregnancy, and for treatment of upper tract infections 4, 6

  • Long-term use carries risks of serious adverse effects including pulmonary reactions and polyneuropathy, though short-term therapy (5-7 days) demonstrates good tolerability comparable to other standard regimens 6

Alternative Oral Agents for Streptococcal UTIs

  • Ampicillin 500 mg orally every 8 hours remains highly effective against streptococcal urinary infections and can be used as an alternative oral regimen when nitrofurantoin is contraindicated 1

  • Amoxicillin-clavulanic acid is recommended by WHO guidelines as a first-line option for lower UTIs with generally high susceptibility rates maintained against common uropathogens 4

Common Pitfalls to Avoid

  • Do not use nitrofurantoin for complicated UTIs, pyelonephritis, or any infection with systemic symptoms, as tissue penetration is inadequate for these conditions 1

  • Do not prescribe nitrofurantoin in patients with reduced renal function, as the drug requires adequate kidney function to achieve therapeutic urinary concentrations 4, 6

  • Obtain urine culture before treatment if symptoms persist beyond 7 days or recur within 4 weeks, as this may indicate treatment failure requiring culture-directed therapy with a different antimicrobial class 1

References

Guideline

Treatment for Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

In-vitro activity of nitrofurantoin in enterococcus urinary tract infection.

JPMA. The Journal of the Pakistan Medical Association, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Nitrofurantoin--clinical relevance in uncomplicated urinary tract infections].

Medizinische Monatsschrift fur Pharmazeuten, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.